ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1504

High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1322

High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1315

High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1404

Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1083

How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 0989

Human MAIT cell produce IL-17 independently of IL-23 and TL1A

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0924

Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology

(0916–0933) Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1377

Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1475

Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1570

Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1524

Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0903

Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 0997

Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1433

Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1298

Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups

(1272–1305) Pediatric Rheumatology – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].